...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!
Message: COVID-19 "competition" to keep an eye on.
- A Phase 1 trial has demonstrated that a new coronavirus treatment helped patients with moderate-to-serious COVID-19 to recover within days, Tel Aviv’s Ichilov Medical Center said on Friday, according to The Times of Israel.
- Out of 30 patients with moderate or severe COVID-19, who received EXO-CD24, 29 have recovered within three to five days. The recovery took “a few days” longer for the other patient, said professor Nadir Arber, the lead researcher.
- Meanwhile, based on the trial conducted in the U.K. in critically ill COVID-19 patients, the rheumatoid arthritis drug Tocilizumab, from Chugai (OTCPK:CHGCY) and Roche (OTCQX:RHHBY), has reduced the mortality rate to 27.3% in combination with sarilumab, from Sanofi (NASDAQ:SNY), compared to 35.8% in patients receiving only the current standard of care.
- Therefore, with a 24% relative decline in risk of death, the combination of immunosuppressive drugs, administered intravenously within 24 hours of entering intensive care, has also helped patients to leave the ICU between 7 - 10 days earlier on average.
- The results have prompted the U.K. health authorities to update COVID-19 guidance, encouraging the use of tocilizumab in severely ill patients.
3 Recommendations
Loading...
Loading...
New Message
Please
login
to post a reply